The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.

<h4>Background</h4>Interstitial lung diseases (ILDs) are chronic, parenchymal lung diseases with a variable clinical course and a poor prognosis. Within various clinical courses, acute exacerbation (AE) is a devastating condition with significant morbidity and high mortality. The aim of...

Full description

Bibliographic Details
Main Authors: Jae Ha Lee, Ji Hoon Jang, Jin Han Park, Hang-Jea Jang, Chan Sun Park, Sunggun Lee, Seong-Ho Kim, Ji Yeon Kim, Hyun Kuk Kim
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0255365
id doaj-3ba546534f9944649dc737960238aea9
record_format Article
spelling doaj-3ba546534f9944649dc737960238aea92021-08-03T04:31:44ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01167e025536510.1371/journal.pone.0255365The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.Jae Ha LeeJi Hoon JangJin Han ParkHang-Jea JangChan Sun ParkSunggun LeeSeong-Ho KimJi Yeon KimHyun Kuk Kim<h4>Background</h4>Interstitial lung diseases (ILDs) are chronic, parenchymal lung diseases with a variable clinical course and a poor prognosis. Within various clinical courses, acute exacerbation (AE) is a devastating condition with significant morbidity and high mortality. The aim of this study was to investigate the role of interleukin-6 (IL-6) to predict AE and prognosis in patients with ILD.<h4>Methods</h4>Eighty-three patients who were diagnosed with ILD from 2016 to 2019 at the Haeundae Paik Hospital, Busan, South Korea, were included and their clinical data were retrospectively analyzed.<h4>Results</h4>The median follow-up period was 20 months. The mean age was 68.1 years and 65.1% of the patients were men with 60.2% of patients being ever-smokers. Among ILDs, idiopathic pulmonary fibrosis was the most common disease (68.7%), followed by connective tissue disease-associated ILD (14.5%), cryptogenic organizing pneumonia (9.6%), and nonspecific interstitial pneumonia (6.0%). The serum levels of IL-6 were measured at diagnosis with ILD and sequentially at follow-up visits. During the follow-ups, 15 (18.1%) patients experienced an acute exacerbation (AE) of ILD and among them, four (26.7%) patients died. In the multivariable analysis, high levels of IL-6 (OR 1.014, 95% CI: 1.001-1.027, p = 0.036) along with lower baseline saturations of peripheral oxygen (SpO2) were independent risk factors for AE. In the receiver operating characteristic curve analysis, the area under the curve was 0.815 (p < 0.001) and the optimal cut-off value of serum IL-6 to predict AE was 25.20 pg/mL with a sensitivity of 66.7% and specificity of 80.6%. In the multivariable Cox analysis, a high level of serum IL-6 (HR 1.007, 95% CI: 1.001-1.014, p = 0.018) was only an independent risk factor for mortality in ILD patients.<h4>Conclusions</h4>In our study, a high level of serum IL-6 is a useful biomarker to predict AE and poor prognosis in patients with ILD.https://doi.org/10.1371/journal.pone.0255365
collection DOAJ
language English
format Article
sources DOAJ
author Jae Ha Lee
Ji Hoon Jang
Jin Han Park
Hang-Jea Jang
Chan Sun Park
Sunggun Lee
Seong-Ho Kim
Ji Yeon Kim
Hyun Kuk Kim
spellingShingle Jae Ha Lee
Ji Hoon Jang
Jin Han Park
Hang-Jea Jang
Chan Sun Park
Sunggun Lee
Seong-Ho Kim
Ji Yeon Kim
Hyun Kuk Kim
The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
PLoS ONE
author_facet Jae Ha Lee
Ji Hoon Jang
Jin Han Park
Hang-Jea Jang
Chan Sun Park
Sunggun Lee
Seong-Ho Kim
Ji Yeon Kim
Hyun Kuk Kim
author_sort Jae Ha Lee
title The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
title_short The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
title_full The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
title_fullStr The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
title_full_unstemmed The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
title_sort role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2021-01-01
description <h4>Background</h4>Interstitial lung diseases (ILDs) are chronic, parenchymal lung diseases with a variable clinical course and a poor prognosis. Within various clinical courses, acute exacerbation (AE) is a devastating condition with significant morbidity and high mortality. The aim of this study was to investigate the role of interleukin-6 (IL-6) to predict AE and prognosis in patients with ILD.<h4>Methods</h4>Eighty-three patients who were diagnosed with ILD from 2016 to 2019 at the Haeundae Paik Hospital, Busan, South Korea, were included and their clinical data were retrospectively analyzed.<h4>Results</h4>The median follow-up period was 20 months. The mean age was 68.1 years and 65.1% of the patients were men with 60.2% of patients being ever-smokers. Among ILDs, idiopathic pulmonary fibrosis was the most common disease (68.7%), followed by connective tissue disease-associated ILD (14.5%), cryptogenic organizing pneumonia (9.6%), and nonspecific interstitial pneumonia (6.0%). The serum levels of IL-6 were measured at diagnosis with ILD and sequentially at follow-up visits. During the follow-ups, 15 (18.1%) patients experienced an acute exacerbation (AE) of ILD and among them, four (26.7%) patients died. In the multivariable analysis, high levels of IL-6 (OR 1.014, 95% CI: 1.001-1.027, p = 0.036) along with lower baseline saturations of peripheral oxygen (SpO2) were independent risk factors for AE. In the receiver operating characteristic curve analysis, the area under the curve was 0.815 (p < 0.001) and the optimal cut-off value of serum IL-6 to predict AE was 25.20 pg/mL with a sensitivity of 66.7% and specificity of 80.6%. In the multivariable Cox analysis, a high level of serum IL-6 (HR 1.007, 95% CI: 1.001-1.014, p = 0.018) was only an independent risk factor for mortality in ILD patients.<h4>Conclusions</h4>In our study, a high level of serum IL-6 is a useful biomarker to predict AE and poor prognosis in patients with ILD.
url https://doi.org/10.1371/journal.pone.0255365
work_keys_str_mv AT jaehalee theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT jihoonjang theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT jinhanpark theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT hangjeajang theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT chansunpark theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT sunggunlee theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT seonghokim theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT jiyeonkim theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT hyunkukkim theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT jaehalee roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT jihoonjang roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT jinhanpark roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT hangjeajang roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT chansunpark roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT sunggunlee roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT seonghokim roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT jiyeonkim roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
AT hyunkukkim roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
_version_ 1721224055376314368